{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:12:55Z","timestamp":1784945575324,"version":"3.55.0"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia\/small lymphocytic lymphoma, Waldenstr\u00f6m macroglobulinemia, and previously treated chronic graft-versus-host disease, and for mantle cell lymphoma in Europe. Patients with difficulty swallowing capsules or tablets may require alternative formulations or administration options to optimize treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the relative bioavailability of ibrutinib oral suspension relative to capsule or tablet formulations and to examine compatibility for optimal administration methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Relative bioavailability of ibrutinib oral suspension was evaluated in healthy volunteers or patients in comparison to capsule or tablet formulations. Dose recovery and delivery, presence of impurities, particle size, and hold time were evaluated after in vitro mock oral suspension administration via syringe and nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Clinical bioavailability was comparable for ibrutinib oral suspension and capsules (420\u2009mg\/day) under the fasted state in healthy volunteers. Dose-normalized pharmacokinetic values were similar across ibrutinib formulations in patient studies. All evaluated enteral tubes achieved 90%\u2013110% ibrutinib dose recovery regardless of tube type or syringe after 2\u2009\u00d7\u20093\u2009mL water rinses. Oral suspension preservative may be adsorbed into enteral tubes after a 60-minute hold time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ibrutinib oral suspension bioavailability was comparable with ibrutinib tablet and capsule formulations. When dosed via standard enteral tube administration methods, ibrutinib oral suspension is stable and compatible with polyurethane, silicone, or polyvinyl nasogastric or PEG tubes. To ensure full dose recovery and prevent drug preservative adsorption into tubes, ibrutinib oral suspension should be administered immediately and followed by two rinses of 3\u2009mL of water each. Ibrutinib oral suspension is a viable BTKi treatment option for patients requiring or preferring alternatives to oral capsules and tablets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251399466","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T18:01:42Z","timestamp":1766599302000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route"],"prefix":"10.1177","volume":"16","author":[{"given":"Jonas","family":"Paludo","sequence":"first","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2288-1430","authenticated-orcid":false,"given":"Lisa","family":"Nodzon","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Woot de Trixhe","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Raritan, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Pacia","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Mavani","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, a Johnson &amp; Johnson company, Horsham, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harisha","family":"Atluri","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Huemann","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Shelly","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yemin","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"Imbruvica (ibrutinib) [prescribing information]. South San Francisco CA: Pharmacyclics LLC 2024."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1908213"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795159"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.021"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.10.029"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03380-0"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.07.033"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7317.850"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04495-2"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15463"},{"issue":"9","key":"e_1_3_5_17_2","first-page":"411","article-title":"Medication-related swallowing difficulties may be more common than we realise","volume":"15","author":"Strachan I","year":"2005","unstructured":"Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realise. Pharm Practice 2005; 15(9): 411\u2013414.","journal-title":"Pharm Practice"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S164406"},{"key":"e_1_3_5_19_2","volume-title":"International Congress on Hematologic Malignancies","author":"Sarosiek S","unstructured":"Sarosiek S, Nodzon LA, Salkar M, et al. Prevalence and economic burden of dysphagia in patients with chronic lymphocytic leukemia and Waldenstr\u00f6m macroglobulinemia. Presented at International Congress on Hematologic Malignancies, Miami Beach, FL, USA, 29 February\u20133 March 2024."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2708-9"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S165713"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-024-10703-4"},{"key":"e_1_3_5_23_2","unstructured":"Patients Association. Survey of medicines related care of residents with dysphagia in care homes https:\/\/www.rosemontpharma.com\/wp-content\/uploads\/2023\/11\/Ref-3-Survey-of-medicines-related-care-of-residents-with-dysphagia-in-care-homes.pdf (2015 accessed 18 July 2024)."},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S277238"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1417-0"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc1997.6.5.382"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics5010011"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2012.04.005"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251399466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251399466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251399466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:18:02Z","timestamp":1777591082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251399466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"alternative-id":["10.1177\/20406207251399466"],"URL":"https:\/\/doi.org\/10.1177\/20406207251399466","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251399466"}}